Baricitinib as monotherapy and with topical corticosteroids in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis of dose-response.

Front Allergy · 2024 · PMC11602504 · PMID 39610670

Europe PMC DOI

hedged sentence

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantp < 0.00001actually significant

The 2 mg dosage also showed a highly significant effect ( p < 0.00001, I 2 = 12%), with low heterogeneity.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.